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Michael C. Jensen,1,2 Leslie Popplewell,2 Laurence J. Cooper,2 David DiGiusto,2
Michael Kalos,1 Julie R. Ostberg,1 Stephen J. Forman1,2Immunotherapeutic ablation of lymphoma is a conceptually attractive treatment strategy that is the subject of
intense translational research. Cytotoxic T lymphocytes (CTLs) that are genetically modified to express
CD19- or CD20-specific, single-chain antibody–derived chimeric antigen receptors (CARs) display HLA-
independent antigen-specific recognition/killing of lymphoma targets. Here, we describe our initial experi-
ence in applying CAR-redirected autologous CTL adoptive therapy to patients with recurrent lymphoma.
Using plasmid vector electrotransfer/drug selection systems, cloned and polyclonal CAR1 CTLs were gen-
erated from autologous peripheral blood mononuclear cells and expanded in vitro to cell numbers sufficient
for clinical use. In 2 FDA-authorized trials, patients with recurrent diffuse large cell lymphoma were treated
with cloned CD81 CTLs expressing a CD20-specific CAR (along with NeoR) after autologous hematopoi-
etic stem cell transplantation, and patients with refractory follicular lymphoma were treated with polyclonal
T cell preparations expressing a CD19-specific CAR (along with HyTK, a fusion of hygromycin resistance and
HSV-1 thymidine kinase suicide genes) and low-dose s.c. recombinant human interleukin-2. A total of 15 in-
fusions were administered (5 at 108cells/m2, 7 at 109cells/m2, and 3 at 2  109cells/m2) to 4 patients. Overt
toxicities attributable to CTL administration were not observed; however, detection of transferred CTLs in
the circulation, as measured by quantitative polymerase chain reaction, was short (24 hours to 7 days), and
cellular antitransgene immune rejection responses were noted in 2 patients. These studies reveal the primary
barrier to therapeutic efficacy is limited persistence, and provide the rationale to prospectively define T cell
populations intrinsically programmed for survival after adoptive transfer and to modulate the immune status
of recipients to prevent/delay antitransgene rejection responses.
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Although conventional chemotherapy, radiation
therapy, and antibody therapy can be efficacious in
treating lymphoma, relapse and progressive disease
are the major sources of patient morbidity and mortal-
ity [1,2]. Experimental evidence that the cellular
immune system can eradicate lymphoma provides
a basis for the development of therapies aimed at
amplifying antitumor immune responses [3,4]. The
adoptive transfer of lymphoma-specific T cells is one
strategy to augment antilymphoma immunity. A sig-
nificant challenge to executing this strategy is the iso-
lation of T cells specifically reactive to lymphoma.
Alternately, the ex vivo derivation of tumor-specific
T lymphocytes by genetic modification to express
tumor-targeting chimeric antigen receptors (CARs)
is a rapidly evolving focus of translational cancer1245
1246 Biol Blood Marrow Transplant 16:1245-1256, 2010M. C. Jensen et al.immunotherapy [5,6]. Antibody-based CARs are
HLA-unrestricted and thus can be used in patient pop-
ulations with target-antigen–positive tumors.
We have constructed 2 CARs specific for the B cell
lineage antigens CD20 and CD19 for the purpose of
targeting lymphomas and leukemias [7,8]. When
expressed in cytotoxic T lymphocytes (CTLs), these
CARs redirect effector cells to lyse B-lineage lymph-
oma targets [7,8]. Here we report our initial clinical
experience in manufacturing and infusing autologous
T cells expressing CD20R or CD19R in patients with
relapsed B cell lymphoma under City of Hope–held
FDA-authorized trials BB-IND-8513/IRB 98142 and
BB-IND-11411/IRB 01160, respectively.MATERIALS AND METHODS
Patients
City of Hope Internal Review Board (IRB) proto-
cols 98142 and 01160 were activated for patient accrual
following IRB and Institutional Biological Safety
Committee approval, FDA authorization (BB-IND-
8513 and BB-IND-11411, respectively), and National
Institutes of Health Office of Biotechnology Activities
registration (9907-330 and 0207-543, respectively). In
brief, for IRB 98142, patients were eligible if they had
immunohistopathologically documented CD201 dif-
fuse large cell lymphoma (DLCL) with a history of
recurrent or refractory disease and did not have central
nervous system metastases. After leukapheresis, pa-
tients began salvage/mobilization chemotherapy,
then underwent hematopoietic stem cell transplanta-
tion (HSCT). The first of 3 escalating-doseT cell infu-
sions was given at 28 days post-HSCT. For IRB
protocol 01160, patients were eligible if they had path-
ologically documented follicular lymphoma (FL) with
evidence of progression after previous rituximab ther-
apy and did not have central nervous systemmetastases
or a history of allogeneic HSCT. These patients were
enrolled no sooner than 3 weeks after their most recent
cytotoxic chemotherapy.Plasmid Vectors
The plasmid expression vectors encoding the
CD20R chimeric immunoreceptor and the neomycin
phosphotransferase cDNAs and the CD19R chimeric
immunoreceptor and the selection-suicide HyTK (a
fusion of hygromycin resistance andHSV-1 thymidine
kinase suicide genes) cDNAs have been described
previously [7,8] (Figure S1A). In brief, the chimeric
construct consists of VH and VL gene segments of
the CD20-specific Leu-16 or CD19-specific FMC63
monoclonal antibodies (mAbs), an IgG hinge-CH2-
CH3 region, a CD4 transmembrane region, and the
cytoplasmic domain of the CD3z chain (Figure S1B).Isolation, Transfection, Selection, Cloning, and
Expansion of T Cells
The methods for OKT3 stimulation of peripheral
blood mononuclear cells (PBMCs), and for PBMC
electroporation, selection, cloning (IRB 98142 only),
and subsequent growth using the rapid expansion
method (REM), consisting of recursive 14-day cycles
of activation with OKT3, recombinant human inter-
leukin (rHuIL)-2, and PBMC/lymphoblastoid cell
line (LCL)-irradiated feeders, have been described
previously [9]. The overall T cell product manufactur-
ing schemas for each trial are depicted in Figure S1C.
Cell Product Quality Control Tests
The cell product quality control tests (QCTs) per-
formed and the requisite test results for product release
are summarized in Table S1.
Confirmation of Plasmid Vector Integration (IRB
98142 Only)
A single site of plasmid vector chromosomal inte-
gration was confirmed by Southern blot analysis of
XbaI/HindIII-digested T cell genomic DNA using
a 420-bp NeoR-specific probe generated using the
pcDNA3.1(-) plasmid as a template [9]. The pass crite-
rion of this test was defined as detection of a single
band.
Confirmation of CAR Expression
Western blot analysis for CAR expression has been
described previously [10]. In brief, reduced whole-cell
lysates are subjected to Western blot analysis with an
anti-human CD3-z (cytoplasmic tail)-specific mAb
8D3 (BD Pharmingen, San Diego, CA). This probe
detects both the 16-kDa endogenous z and the 66-
kDa CAR z. Pass criteria were defined as visualization
of both the 16-kDa and 66-kDa bands. Flow cytometry
analysis for surface CAR expression was determined
using a fluorescein isothiocyanate (FITC)-conjugated
Fc-specific antibody (Jackson ImmunoResearch,
West Grove, PA). Pass criteria were defined as unim-
odal positive staining for Fc compared with the
FITC-conjugated isotype control (BD Biosciences,
San Jose, CA).
Surface Phenotype Determination
T cell products were evaluated for cell-surface
phenotype using standard staining and flow cytometric
procedures with FITC-conjugated mAbs (BD Biosci-
ences), followed by analysis on a FACScaliber analyzer
(BD Biosciences). The pass criterion was $90% posi-
tive staining for TCR-ab and CD8 (IRB 98142) or
CD3 (IRB 01160) compared with the isotype control.
Independent of the QCT guidelines, other correlative
surface markers included CD4 for IRB 98142 and both
CD4 and CD8 for IRB 01160.
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Cytolytic activity of CAR1 CTLs against 51Cr-
labeled human lymphoma Daudi cells was assessed as
described previously using a 4-hour chromium release
assay [8]. The pass criterion was$50% specific lysis at
an effector-to-target ratio of 25:1.
Viability
Viability was determined by standard trypan blue
dye exclusion. The pass criterion was .90% viability.
Sensitivity to Ganciclovir Ablation (IRB 01160
Only)
To test for acquired cytocidal sensitivity to ganci-
clovir (GCV), aliquots of cells were harvested from
5-day REM cultures, then maintained for 14 days in
37.5 U/mL rHuIL-2 with or without 1 mM GCV.
Then the cells were harvested and subjected to viability
testing. The pass criterion was #25% viability in the
GCV-treated cultures.
Assay for Antigen/IL-2–Independent Growth
First, 5 106 cells were washed and plated in anti-
gen- and IL-2–free culturemedia at the end of a 14-day
REM cycle. Parallel cultures of Jurkat T cells (Ameri-
can Type Culture Collection, Manassas, VA) (IRB
98142) or T cells cultured in the presence of 37.5 U/
mL rHuIL-2 (IRB 01160) served as controls for expan-
sion and viability. For IRB 98142, following an 11-day
incubation, cultures were harvested, counted using try-
pan blue, plated into 96-well plates at 6000 viable cells
per well, and pulsed with 1 mCi of 3H-TdR. DNA was
harvested following a 4-hour incubation at 37C. For
IRB 01160, viable cell numbers of 14-day cultures
were determined by flow cytometry as described
previously [11]. Release criteria specified that cells
must exhibit\10% of the Jurkat cpm (IRB 98142) or
\10% of the IL-21 control cell number (IRB 01160).
Sterility
Sterility tests were performed according to an FDA
Center for Biologics and Evaluation of Research–man-
dated schedule. Aliquots of media from the T cell cul-
tures were plated onto bacterial and fungal growth
media. Mycoplasma detection was conducted on me-
dia aliquots using the Gen-Probe Mycoplasma Tissue
Culture-NI Rapid Detection System (Gen-Probe, San
Diego, CA), and endotoxin levels were determined by
enzyme-linked immunosorbent assay. Pass criteria
were negative bacterial, fungal, and mycoplasma
results, along with an endotoxin level\5 EU/kg recip-
ient weight.
Adoptive Transfer of T Cells
Processed and cryopreserved cell banks were
thawed and expanded in culture to the desired cellnumbers before being resuspended in 0.9% NaCl
with 2% human serum albumin in a clinical reinfusion
bag. T cells were reinfused i.v. over 30 minutes
through either a central line or an age-appropriate
sized i.v. catheter inserted into a peripheral vein. The
infusion bag was mixed gently every 5 minutes during
the infusion. The intrapatient dose escalation plan is
shown schematically in Figure S2. In IRB 01160, flu-
darabine (Flu) was administered after the first T cell
infusion as a potential nonmyeloablative (NMA)
immunosuppressive regimen for attenuating possible
rejection responses against the transferred T cells.
The guidelines provided in the National Cancer Insti-
tute’s (NCI) Common Toxicity Criteria, version 2.0
(https://ctep.ifo.nih.gov/l) were followed for the mon-
itoring of toxicity and adverse event reporting. Rules
for dose escalation, de-escalation, and cancellation
were strictly enforced and resulted in 3 of the 4 treated
patients deviating from the planned infusion cell dose
escalation at least once.
In Vivo Persistence of Transferred T Cells
For IRB 98142, PBMCs from heparinized periph-
eral blood samples were isolated and analyzed for per-
centage of transfected cells by quantitative polymerase
chain reaction (qPCR) as described previously [12]
using primers and probes to quantify CD20R copy
number (details available on request).
For IRB 01160, samples were received, processed,
stored, and analyzed in accordance with current good
laboratory practice guidelines. A validated qPCR-
based assay to quantify CD19R plasmid vector DNA
in samples was developed and performed using an
MJ Research DNA engine with a Chromo 4 continu-
ous fluorescence detector qPCR module (Bio-Rad,
Hercules, CA). Real-time qPCR was performed in
a 20-mL reaction mixture volume containing 50 ng
DNA, 10 mL of IQ SYBR Green Supermix (Bio-Rad;
catalog no. 170-8880), and 0.5 pmol of each primer.
Quantification of the CD19R transgene sequence in
DNA isolated from patient PBMCs was evaluated us-
ing qPCR to amplify a 182-nucleotide fragment that
spanned the CD4 transmembrane–zeta junction
within the transgene coding sequence, and a standard
curve derived by dilution of DNA isolated from a clone
with a single integration of the CD19R transgene
(primers, probes, and amplification conditions avail-
able on request). The qualification studies for this am-
plification reaction demonstrated no amplification
from healthy donor-derived PBMCs (n 5 5), whereas
the transgene sequence could be quantified in
a PBMC sample if the transgene containing DNA
composed as little as 0.1% of the total DNA sample.
Analysis of Antitransgene Rejection Responses
Pretreatment and post-treatment PBMCs (on days
175, 177, and 150 from UPN006, UPN009, and
1248 Biol Blood Marrow Transplant 16:1245-1256, 2010M. C. Jensen et al.UPN035, respectively) were first stimulated with irra-
diated therapeutic T cells (3000 rads) or LCLs with
and without pcDNA3.1(-) plasmid (8000 rads) plus ir-
radiated pretreatment PBMCs as feeder cells at a 10:1
responder-to-stimulator ratio in RPMI 1640 (Irvine
Scientific, Santa Ana, CA) supplemented with 2 mM
L-glutamine (Irvine Scientific), 25 mM Hepes (Irvine
Scientific), 100 U/mL penicillin, 0.1 mg/mL strepto-
mycin (Irvine Scientific), and 10% heat-inactivated
human serum. One week later, the same irradiated
stimulator, as well as irradiated pretreatment PBMC
feeders (3500 rads), were added at a 1:1:1 responder-
to-stimulator-to-feeder ratio. This stimulation schema
was repeated up to 2more times (once weekly) until suf-
ficient numbers were obtained for chromium-release
assays. Cytolytic activity of these stimulated PBMC
against 51Cr-labeled targets was analyzed as described
previously using a 4-hour chromium-release assay [8].
For IRB 01160, cellular antitransgene immune re-
sponses were evaluated directly ex vivo using a combina-
tion of T cell receptor (TCR) Vb spectratyping and
CD107 degranulation assays. For the TCR Vb spectra-
typing analysis, RNA was isolated from PBMC
collected before and after infusion using the
RNAqueous-4 PCR Kit for Isolation of DNA-free
RNA (Applied Biosystems/Ambion, Austin, TX), and
cDNA was then synthesized using the iScript cDNA
Synthesis Kit (Bio-Rad). TCR Vb spectratyping analy-
sis was performed on cDNA samples essentially as de-
scribed previously [13] using pools of Vb-specific
primers. A parallel series of amplifications using
cDNA generated from pooled healthy donor PBMCs
was performed as a quality control for amplification of
each Vb family. Aliquots of the amplification mixes
were run on sequencing gels, followed by analyses using
Genemapper v3.7 software (Applied Biosystems). The
CD107 degranulation/mobilization assay was per-
formed essentially as described previously [14], using
patient PBMCs collected before and after infusion as ef-
fectors and infused T cell product or OKT3-expanded
preinfusion PBMCs (i.e., autologous T cells) as targets.
To detect spontaneous degranulation, a control sample
without target cells was included in every experiment.
FITC-conjugated anti-CD107a and anti-CD107b
(BD Biosciences) were added directly to the tubes be-
fore incubation. After 5 hours of coincubation, cells
were washed twice and stained with PE-Cy5-
conjugated anti-CD8b and PE-conjugated anti-TCR
Vb23 (Beckman Coulter, Fullerton, CA) for 30minutes
at room temperature in the dark, rewashed, and ana-
lyzed on a FC500 flow cytometer using FCS Express
v3.0 software (Beckman Coulter), with gating on
CD8b1 and Vb231 lymphocytes.
Serologic Anti-CAR Immune Response Analysis
Serum was isolated from patient blood samples
collected in red-top (no additive) tubes using anestablished laboratory standard operating procedure
and a qualified assay to detect CAR-specific serologic
responses in samples. Samples were allowed to clot
for 2-1/2 hours at room temperature, then centrifuged
at 1000  g for 15 minutes at 4C. Serum was col-
lected, aliquoted, and frozen immediately at 280C.
Flow cytometry detection of potential serum antibody
responses against the anti-CD19R transgene was
performed using parental versus CD19R-expressing
Jurkat cell lines as indicator cell lines. The presence
of antibodies in patient serum that specifically bound
to CD19R1 Jurkat cells was evaluated by a subsequent
incubation with FITC-conjugated AffiniPure F(ab’)2
fragment goat anti-human IgG (Fcg; Jackson Immu-
noResearch). The cutoff for a negative response was
established by defining the 95% one-sided prediction
interval using a pool of non–CAR-reactive serum
samples from healthy volunteers.RESULTS
Patient Characteristics
The patients in these studies either had DLCL
(BB-IND 8513/IRB 98142) or follicular non-
Hodgkin lymphoma (NHL; BB-IND 11411/IRB
01160) (Table S2). One of the 4 research participants
had bulky disease, including sites at the neck, chest,
lymph nodes, and pelvis, at the time of enrollment.
Three of the 4 participants had received rituximab
(chimeric mAb specific for CD20) therapy before the
first infusion of therapeutic T cells. The average dura-
tion of time from leukapheresis to first infusion was
106 days, and was affected by the time required to
manufacture the T cell product and/or the timing of
the patient’s recovery from salvage therapy.
Generation of Genetically Modified T Cells
Cell products meeting all quality control release
tests (Table S1) were successfully generated for 2 of
the 5 patients enrolled on IRB 98142, and for both pa-
tients enrolled on IRB 01160. The failure to release
products for 3 of the patients enrolled on IRB 98142
stemmed from an inability to isolate T cell clones
that expressed CD8, expressed endogenous TCR, or
expanded adequately in vitro. The results of Southern
blot analysis indicating the desired single-site inser-
tions of the CD20R transgene within the released
clones of IRB 98142 are depicted in Figure 1.Western
blot and cell-surface expression profiles of T cell
products for both trials are also depicted, confirming
expression of the CAR protein. These cells were fur-
ther subjected to flow cytometry analysis for confirma-
tion of the T cell subset markers CD4, CD8, and either
TCR-ab or CD3. All of the cell products used in ther-
apy also exhibited redirected killing of CD191 and
CD201 human Daudi lymphoma targets in 4-hour
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CTL clones to lyse CD191 CD201 Daudi targets was determined in a 4-hour 51Cr release assay; ganciclovir (GCV) sensitivity using a flow cytometry–
based assay for viable cell numbers after 14 days of culture with either rHuIL-2 or rHuIL-21 GCV; assays for IL-2 dependence were performed using
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lines retained their dependence on exogenous
rHuIL-2 for survival and proliferation, and the
HyTK-expressing lines of IRB 01160 tested positive
for sensitivity to GCV-mediated ablation.Treatment Experience
As depicted in Figure 2, the intrapatient dose esca-
lations were carried out as planned (compare with
Figure S2), with the exception that the 1010/m2 cell
dose was never given in IRB 98142 because of protocol
toxicity dose modification rules (UPN006 and
UPN009). Indeed, because of grade 2 hepatic toxic-
ities that were noticed with the first infusion dose of
108/m2 in UPN006, the second infusion was repeated
at 108/m2, followed by an escalation to 109/m2 for the
third infusion. Patient UPN009 exhibited a drop in he-
moglobin after the second infusion that, although clin-
ically insignificant (from 10.6 to 8.6), represented
a Common Toxicity Criteria grade change from grade
1 to grade 2 anemia status, requiring repetition of the109/m2 dose for the third infusion based on the proto-
col’s defined rules for dose escalation. In UPN006, the
second infusion was cancelled and rescheduled because
of a puncture in the bag, which compromised the in-
tegrity of the T cell product. In UPN037, the last in-
fusion was cancelled because of the detection of
contaminated T cell product. Neither myeloablation
(MA) followed by HSCT nor Flu resulted in a drop
in absolute lymphocyte count (ALC) below the normal
range (Table S3).
There were no grade 3 or higher adverse events
with a possible correlation to administration of 108
T cells per m2. However, examination of the adverse
events at 109 T cells per m2 revealed one case of
grade 3 self-limited lymphopenia in both IRB
98142 and IRB 01160, possibly attributed to cell
administration (Table 1). At 2  109 T cells per
m2, grade 3 lymphopenia and grade 3 eosinophilia
each occurred once in IRB 01160; both resolved
spontaneously with no adverse sequelae to the
patients. Overall, the safety profile of this adoptive
transfer therapy was acceptable.
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Although this was a phase I clinical trial with a pri-
mary purpose of determining safety, we also moni-
tored the disease and survival status of each patient.
For IRB 98142 (CD20R; DLCL), UPN006 (last infu-
sion on February 24, 2000) relapsed in September
2001, whereas UPN009 (last infusion on November
22, 2000) continues to be in remission after autologous
HSCT. At the time of the writing of this report, both
UPN006 (after additional treatment) andUPN009 are
alive and in remission. For IRB 01160 (CD19R; FL),
UPN035 (last infusion on May 4, 2006) presentedwith a new diagnosis of CD191/CD201 DLCL in
June 2006, and died in June 2007. UPN037 (last infu-
sion on February 15, 2007) displayed progression on
computed tomography scan in September 2007, and
is currently alive and undergoing additional treatment.
In Vivo Persistence of Transferred T Cells
Quantitative PCR performed to detect CD20R
and CD19R plasmid copy numbers in PBMCs as a sur-
rogate marker of the presence of adoptively transferred
T cells showed varying T cell persistence among pa-
tients (Figure 3). Only 1 of the 4 patients (UPN006)
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Table 1. Adverse Event Summary
IRB Trial
T Cell
Dose, Cells/m2 Event* Occurrences
98142 109 Lymphopenia 1
01160 109 Lymphopenia 1
2  109 Lymphopenia 1
Eosinophilia 1
IRB indicates internal review board; NCI, National Cancer Institute.
*Only eventsof grade 3or higher, according to theNCICommonToxicity
Criteria, with possible attribution to T cell administration are reported.
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after the first infusion of 108 cells/m2. A detectable
level of transferred T cells at 1 week after infusion of
109 cells/m2 was found in only 2 of the 7 higher doses
(UPN006 infusion 3 and UPN009 infusion 2), and at
no time were transferred T cells detected at 1 week af-
ter infusion of 2  109 cells/m2. Thus, adoptively
transferred T cell persistence did not appear to corre-
late with cell dose. Compared with the persistence af-
ter the initial infusion, UPN009, UPN035, and
UPN037 also displayed significantly reduced levels
of transferred T cells 24 hours after each additional in-
fusion, suggesting the possibility of an antitransgene
immune response mounted against the administered
T cells (Figure 3).0
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Figure 3. Transferred T cells do not persist long term in vivo. Using
real time quantitative PCR, the percent of cells in the PBMC that
were positive for the CD20R (A) or CD19R (B) genes were determined
as an indicator of the relative amount of chimeric receptor expressing T
cells in the PBMC samples collected at the indicated days during the
treatment schedule. Escalating infusion doses are indicated by arrows.
*Cells not harvested.Detection of Transgene-Specific Immune
Responses
For IRB 98142 (CD20R; DLCL), the develop-
ment of cellular immune responses against the infused
T cell products was evaluated. For these analyses,
PBMCs were collected from UPN006 and UPN009
before and after T cell administration, and, after in vi-
tro stimulation, were compared for cytotoxic activity
using chromium-release assays (Figure 4). The use of
irradiated lymphoblastoid cells (xLCLs) to stimulate
the PBMCs resulted in successful lysis of 51Cr-labeled
LCLs, indicating that functional effector cells could be
derived from each patient’s PBMC samples. Interest-
ingly, when the irradiated autologous T cell clones
were used to stimulate the PBMCs, cytotoxic re-
sponses were seen against the 51Cr-labeled T cell clone
only in the posttreatment sample collected from
UPN009 (Figure 4A). This immunoreactivity against
the T cell clone 6D10 used in therapy appeared to be
specific for neomycin phosphotransferase but not the
CAR, because cytotoxic responses could be observed
against 51Cr-labeled LCLs that had been transduced
with the pcDNA3.1(-) vector, which directs the ex-
pression of neomycin phosphotransferase, but lacks
the CD20R transgene (Figure 4B). To better analyze
the specificity of the rejection response, UPN009’s
posttreatment PBMCs that had been stimulated withirradiated 6D10 cells were cloned in limiting dilution;
all clones were similarly specific for NeoR (Figure 4C).
For IRB 01160 (CD19R; FL), the development of
both antibody and cellular immune responses against
the infused T cell products was evaluated. For the an-
tibody analyses, serum collected from UPN035 and
UPN037 at enrollment and after T cell administration
were both negative for antibody reactivity against the
surface-expressed CD19R transgene using a flow
cytometry–based assay (Figure 5A); however, evidence
was found for cell-mediated immunoreactivity against
the infused T cells. Examination of the TCR Vb gene
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PBMCs collected from UPN035 and UPN037 both
before and after T cell administration revealed alter-
ations in the Vb profiles of the posttreatment PBMCs,
with the appearance of unique clonotypes in the post-
infusion samples indicative of a new immunoreactive
response (Figure 5B). Furthermore, flow cytometry
analysis of the TCR Vb231 and Vb141 subpopula-
tions in UPN035’s posttreatment PBMCs collected 2
weeks after the first infusion showed significant surface
CD107 expression, an indicator of lysis-associated de-
granulation, on coculture with the infused T cell prod-uct (Figure 5C and data not shown). This specific
degranulation was not observed with the pretreatment
PBMCs or when the posttreatment PBMCs were co-
cultured with control T cells. Similar flow cytometric
assays could not be carried out with UPN037’s PBMC
because of the lack of commercially available anti-
bodies specific for the TCR Vb genes (Vb15 and
Vb21) that arose in this patient. The pretreatment
and posttreatment PBMCs from UPN035 also were
stimulated in vitro with irradiated LCLs or infused
T cell product and compared for their cytotoxic activ-
ity using chromium-release assays (Figure 5D). As seen
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Biol Blood Marrow Transplant 16:1245-1256, 2010 1253Adoptive Therapy with Redirected T Cells for Lymphoma
1254 Biol Blood Marrow Transplant 16:1245-1256, 2010M. C. Jensen et al.in UPN009 in IRB 98142, functional effector cells
were derived from both of UPN035’s PBMC samples,
but cytolytic activity against the 51Cr-labeled T cells
was seen only in the posttreatment sample. Taken to-
gether, these data suggest that, at least in some cases,
the lack of T cell persistence observed in these 2 trials
was because of immune rejection responses mounted
by the patient’s endogenous T cells.DISCUSSION
More than 55,000 new cases of NHL are diagnosed
each year in the United States, and the incidence of this
disease is increasing [15,16]. Intermediate-grade B cell
lymphomas (ie, diffuse large cell, mantle cell, marginal
zone) and low-grade FLs are the most common sub-
types of NHL, accounting for approximately 80% of
cases. Most patients have widespread disease at the
timeofdiagnosis and are treatedwith somecombination
of chemotherapy, radiation therapy, and rituximab.
Unfortunately, more than two-thirds will relapse with
their disease, and only 10% of these patients can be
salvaged [17]. Efforts to improve survival in recurrent
NHL focus primarily on the use of MA conditioning
and autologous HSCT [18-21], a strategy that is
curative in approximately 46% of selected patients.
However, the selected group of salvageable patients
(aged \60 years, complete remission after primary
treatment, and no known marrow or central nervous
system disease) represents less than one-third of those
with relapsed intermediate grade lymphomas. Patients
with chemotherapy-resistant recurrent disease have
a \15% 5-year event-free survival after HSCT, and
those with refractory disease at the time of transplanta-
tion are rarely cured. Similarly, patientswithmantle cell
lymphoma and low-grade FL, whose disease becomes
refractory to chemotherapy and radiation, have a poor
prognosis despite high-intensity salvage therapy [22-
25]. These findings have prompted the evaluation of
additional strategies to eradicate lymphoma minimal
residual disease after cytoreductive chemotherapy/
radiation/rituximab, including the immunotherapeutic
targeting of malignant B cells with adoptively
transferred antigen-specific T cells.
Here, we have described our initial experience test-
ing the feasibility and safety of lymphoma adoptive
therapy with CTLs genetically modified to express re-
directing CD20- and CD19-specific CARs. Our T cell
production platform relied on plasmid vector electro-
transfer into patient PBMC preparations. Although
this approach facilitated regulatory approval and di-
minished expenses relative to the use of a viral vector
platform, the low efficiency of chromosomal integra-
tion and sustained transgene expression encumbered
the production platform to multiple rounds of activa-
tion/propagation in selection drugs (G418 and hy-
gromycin B). Nevertheless, drug-resistant CAR1T cells were isolated in each of the 7 enrolled patients.
The reason why 3 of the enrolled subjects on protocol
IRB 98142 did not have clones released was that only
CD41CD8- clones were isolated, when the release cri-
teria specified CD4-CD81 clones. This skewed result
in the production runs was specific to lymphoma pa-
tients in this trial and likely reflects the repertoire
changes in these patients because of disease and/or
previous therapy at the time of apheresis for T cell pro-
duction. Another observed limitation in the produc-
tion platform during generation of polyclonal lines in
IRB 01160 was the discordance between CAR expres-
sion and hygromycin resistance. The plasmid vector
used in the trial drives the CAR andHyTK from 2 sep-
arate promoters, allowing chromosomal integration
events that result in deletion of the CAR-encoding
portion of the vector or transcriptional repression of
theCAR promoter. As a result, we found demonstrable
CAR expression in only a subset of polyclonal cell
preparations. This problem potentially can be resolved
in plasmid vectors using single promoter systems in
which the two transgene open reading frames are sep-
arated by an internal ribosome entry site element or di-
rectly integrated into a single polypeptide with
a cleavable linker element. Our group has now rede-
signed our platform to use self-inactivating lentiviral
vectors and shortened ex vivo culture duration (28
days), improving the percentage of CAR-expressing
T cells in polyclonal cell preparations and eliminating
the need for bacterial drug-resistance gene coexpres-
sion.
The primary focus of these studies was to establish
the safety of this approach. In this regard, T cell infu-
sions were well tolerated up to 2  109 cells/m2. The
most common event that could be attributed to T
cell infusion was transient self-limited lymphopenia
lasting less than 7 days. We suspect that this phenom-
enon is related to redistribution of the endogenous cir-
culating repertoire as a consequence of infused cell
product; whether it is based on cytokine/chemokine
elaboration on activation or other mechanisms re-
mains to be delineated. In the 2 patients who demon-
strated immunologic rejection of the infused cell
products, the third and subsequent cell doses in these
2 patients elicited a self-limited (\24 hours) febrile
response with rigors. Despite the dramatic systemic
febrile response, the patients did not exhibit cardiovas-
cular instability or other overt toxicities associated
with a ‘‘cytokine storm’’ syndrome. A toxic death prox-
imal to cell infusion has been recently reported [26] in
a patient with bulky chronic lymphocytic leukemia
who received cyclophosphamide before administra-
tion of redirected T cells expressing a CD19-specific
CAR with both CD28-costimulatory and CD3-z acti-
vation–signaling domains. The lack of serious toxic-
ities in our patients might result from the limited
numbers of circulating B cells at the time of T cell
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MA autologous HSCT, whereas the IRB 01160 pa-
tients experienced B cell reduction as a consequence
of rituxan. However, analysis of peripheral blood sam-
ples after the last T cell infusion, as well as the follow-
up clinical status of these patients, indicate that this
strategy did not result in sustained B cell lymphopenia,
as would be expected based on the transient engraft-
ment of infused effector cells. Another possible expla-
nation for the observed lack of toxicity is an attenuated
cytokine response to activation based on the CAR hav-
ing only a CD3-z–activation domain. Carefully de-
signed future trials should test the effects of these
parameters as they relate to the tolerability of cell infu-
sions.
The NCI’s Surgical Branch has demonstrated that
the frequency and magnitude of melanoma-reactive
tumor-infiltrating lymphocyte (TIL) engraftment can
be enhanced by rendering patients lymphopenic be-
fore adoptive transfer and administering high-dose
rHuIL-2 after transfer. TIL products were previously
difficult to detect in very high numbers after adoptive
therapy engraftment in about 50% of patients treated
with the most intensive lymphodepleting regimens
consisting of MA chemotherapy/TBI with CD34-
selected stem cell rescue. Despite having received
MA HSCT, the patients on IRB 98142 were not lym-
phopenic on day128 when infusion of CD20-specific
CD81 clones commenced. Similarly, the patients on
IRB 01160 were given a 5-day course of Flu at 25
mg/m2/dose without achieving lymphopenia before
T cell transfer. Given the compelling data from the
NCI melanoma trials, we plan to administer T cell
products to lymphoma patients in conjunction with
their autologous HSCT procedure on day 12, when
lymphopenia is profound.
Our experience clearly identifies the issue of trans-
gene immunogenicity as amechanism that limits persis-
tence. The plasmid electrotransfer platform required
that we select drugs for stably integrated clones/lines.
The rejection response observed was cellular and fo-
cused on NeoR in UPN009, whereas the transgene
specificity of the rejection responses in UPN035 and
UPN037 was not characterized further. The ability of
transgenes expressed in T cells to elicit immune re-
sponses after adoptive transfer was clearly established
by the findings of Berger et al. [27], in which the limited
persistence of adoptively transferred HyTK1 T cells
correlated with anti-HyTK transgene-specific immune
responses. Furthermore, although studies by that group
suggest that an NMA immunosuppressive regimen
could prolong the in vivo persistence ofT cells by atten-
uating possible rejection responses [28], Flu applied
after the first dose of T cells in IRB 01160 apparently
failed as an immunopreparative strategy to delete
antitransgene-specific responses. Thus, more effective
immunosuppressive/ lymphodepleting regimens mightbe advantageous for future clinical application. The use
of more efficient vector transduction systems (eg, lenti-
viral vectors or the Sleeping Beauty system [29]) that
would negate the requirement for ex vivo selection
also might allow the omission of NeoR and HyTK.
Even without the selection markers, the CARs them-
selves are expected to be immunogenic based on mouse
single-chain variable fragments and fusion sites in the
chimera. We expect that providing a window for cells
to evade immunologic rejection by patient lymphode-
pletion will be the most practical strategy for limiting
early rejection responses, whereas late rejection re-
sponses have the advantage of eliminating the gene-
modified cells, which, if timed appropriately, could be
exploited as a safety feature.
Poor in vivo persistence is the major problem in
the cancer adoptive therapy field in general, likely
related primarily to the intrinsic programming of
T cells to survive after adoptive transfer. Effector
T cells are inherently short-lived [30], and it has
been suggested that acquisition of an effector pheno-
type during in vitro culture and expansion is a major
reason for the poor survival of transferred T cells
[31]. The adoptive transfer of virus-specific effector
T cells from memory cell precursors can result in
long-term repopulation in humans, however. Thus,
the use of memory T cells, which are known to
self-renew [32], and/or virus specific T cells, which
would receive optimal costimulation after engagement
of their native receptors, as populations for genetic
redirection has become of increasing interest. Indeed,
it has recently been reported that in neuroblastoma
patients, Epstein-Barr virus-specific T cells engi-
neered to coexpress tumor-specific receptors survived
longer than those lacking virus specificity and were
associated with tumor regression or necrosis in half
of the subjects tested [33]. It also was recently reported
that, in a macaque model of adoptive transfer, antigen-
specific CD81 T cell clones derived from central
memory T (TCM) cells persisted long term in vivo,
reacquiring phenotypic and functional properties of
memory T cells and occupying TCM cell niches [34].
Accordingly, we have begun to develop a clinically
compatible immunomagnetic selection system to
isolate TCM cells from human PBMCs for subsequent
processing to generate CAR redirected effector cells.
We propose viral-specific, TCM-derived, anti–tumor
effector cell infusion in lymphoma patients during
profound lymphopenia shortly after autologous
HSCT as the next logical iteration of our translational
research in lymphoma immunotherapy.ACKNOWLEDGMENTS
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